<DOC>
	<DOCNO>NCT01507922</DOCNO>
	<brief_summary>It randomize double-blind parallel phase IV study compare Fenoverine Trimebutine maleate efficacy safety . Study Hypothesis : Fenoverine non-inferior Trimebutine maleate efficacy safety .</brief_summary>
	<brief_title>Comparative Efficacy Safety Fenoverine</brief_title>
	<detailed_description>For subject IBS , Fenoverine Trimebutine administer orally 8 week ; Fenoverine 100mg capsule three time day Trimebutine 150mg tablet three time day . Because one capsule tablet , double dummy design use . Efficacy evaluate end 8 week safety follow 4 week end schedule medication .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Fenoverine</mesh_term>
	<mesh_term>Trimebutine</mesh_term>
	<criteria>18 year age old 60 year age young Diagnosed irritable bowel syndrome use Rome III Criteria Female subject childbearing potential confirm negative urine betahCG test within 7 day prior administration initial dose investigational product . Female subject childbearing potential must agree use contraceptive measure study period . Known allergy hypersensitivity investigational product component formulation Past current diagnosis chronic liver disease ( e.g. , liver cirrhosis , acute hepatitis , alcoholic hepatitis , chronic alcohol abuse HCC ) Past current diagnosis Myopathy Subject serious renal disease Known medical condition assess investigator inappropriate study Continuous use NSAIDS , analgesic , steroid , immunosuppressant . Continuous use HMGCoA reductase inhibitor fibrates low blood lipid level Pregnant , lactating , plan pregnant woman Evidence abuse drug alcohol within 6 month prior screen Participation clinical trial within 3 month prior enrollment elapse less 5 half life previous investigational product last dose . Unable submit inform consent comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Fenoverine</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>BSS</keyword>
</DOC>